Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

Ranjana H. Advani, MD, Stephen M. Ansell, M.D., Ph.D., Mary J Lechowicz, MD, Anne W Beaven, MD, Fausto R. Loberiza, Jr., MD, MS, Kenneth R Carson, MD, Andrew M Evens, DO, MSc, Francine M. Foss, MD, Steven M. Horwitz, MD, Barbara Pro, MD, Lauren Pinter-Brown, MD, Sonali M. Smith, MD, Andrei R. Shustov, MD, Kerry J. Savage, MD, MSc, Julie M Vose, MD, MBA

Blood (2013) 122 (21): 3044.

https://doi.org/10.1182/blood.V122.21.3044.3044

Published: 2013

Journal Articles

Development Of a Human IgM Secreting Model Of Rpci-WM1 Through Xenografting In SCID Mice For In Vivo Drug Evaluation

Kasyapa S. Chitta, PhD, Aneel Paulus, MD, MS, Sharoon Akhtar, Maja Kuranz, Sikander Ailawadhi, M.D., Kena Miller, A.R.N.P, Candido E. Rivera, MD, Gerardo Colon-Otero, MD, Vivek Roy, M.D., Stephen M Ansell, M.D, Ph.D., Anne J. Novak, PhD, Peter Martin, MD, Morton Coleman, MD, Asher Chanan-Khan, MD

Blood (2013) 122 (21): 3081.

https://doi.org/10.1182/blood.V122.21.3081.3081

Published: 2013

Journal Articles

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma

Luis F. Porrata, MD, Kay M. Ristow, Thomas M Habermann, MD, Thomas E Witzig, MD, Joseph P. Colgan, MD, David J. Inwards, MD, Stephen M Ansell, M.D. Ph.D., Ivana N. Micallef, MD, Patrick B. Johnston, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2013) 122 (21): 4306.

https://doi.org/10.1182/blood.V122.21.4306.4306

Published: 2013

Journal Articles

Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas

Stephen M Ansell, M.D., Ph.D., Lucy S. Hodge, PharmD, Ph.D., Frank Secreto, Michelle Manske, Esteban Braggio, Ph.D., TAmmy Price-Troska, Steven Ziesmer, Ying Li, Sarah Johnson, Steven Hart, Jean-Pierre Kocher, George Vasmatzis, PhD, Asher Chanan-Khan, MD, Morie Abraham Gertz, MD, Rafael Fonseca, MD, Ahmet Dogan, MD, PhD, James R Cerhan, MD, PhD, Anne J. Novak, PhD

Blood (2013) 122 (21): 245.

https://doi.org/10.1182/blood.V122.21.245.245

Published: 2013

Journal Articles

Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era

James R Cerhan, MD, PhD, Grzegorz S. Nowakowski, MD, Matthew J Maurer, MS, Bridget Charbonneau, PhD, Herve Ghesquieres, MD, PhD, Anne J. Novak, Ph.D., Yan W Asmann, PhD, Ahmet Dogan, MD, PhD, Svetomir N. Markovic, MD, PhD, Carrie A. Thompson, MD, Stephen M. Ansell, M.D., Ph.D., George J. Weiner, MD, Brian K Link, MD, Thomas M Habermann, MD, Susan L Slager, PhD

Blood (2012) 120 (21): 149.

https://doi.org/10.1182/blood.V120.21.149.149

Published: 2012

Journal Articles

IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia

Lucy S. Hodge, PharmD, Ph.D., Steve Ziesmer, Frank J Secreto, Ph.D., Zhi-Zhang Yang, MD, Anne Novak, Morie Abraham A Gertz, MD, Stephen M Ansell, M.D., Ph.D.

Blood (2012) 120 (21): 1554.

https://doi.org/10.1182/blood.V120.21.1554.1554

Published: 2012

Journal Articles

Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI

Laura S. Jacobus, MS, Julianne Lunde, MA, Matthew J Maurer, MS, Ahmet Dogan, MD, PhD, Sergei I Syrbu, MD, Cristine Allmer, Anne J. Novak, Ph.D., James R Cerhan, MD, PhD, Grzegorz S. Nowakowski, MD, Susan L Slager, PhD, Thomas E. Witzig, MD, Carrie A. Thompson, MD, George J. Weiner, MD, Thomas M Habermann, MD, Stephen M. Ansell, M.D., Ph.D., Brian K Link, MD

Blood (2012) 120 (21): 1563.

https://doi.org/10.1182/blood.V120.21.1563.1563

Published: 2012

Journal Articles

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)

Luis F. Porrata, MD, Kay M. Ristow, Thomas M. Habermann, Thomas E Witzig, Joseph P. Colgan, MD, David J. Inwards, MD, Stephen M. Ansell, M.D., Ph.D., Ivana N. Micallef, MD, Patrick B. Johnston, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2012) 120 (21): 1527.

https://doi.org/10.1182/blood.V120.21.1527.1527

Published: 2012

Journal Articles

Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL , HLA-DRA , GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies

Blood (2012) 120 (21): 3637.

https://doi.org/10.1182/blood.V120.21.3637.3637

Published: 2012

Journal Articles

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Isere Kuiatse, Ph.D., Sheeba K. Thomas, MD, Donna M. Weber, M.D., Adam M. Stein, B.S., Michael Wang, M.D., Jatin J. Shah, M.D., Steven P. Treon, M.D., Ph.D., Stephen M. Ansell, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 3723.

https://doi.org/10.1182/blood.V120.21.3723.3723

Published: 2012

Journal Articles

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, Stephen M. Ansell, M.D., Ph.D., Joseph D. Rosenblatt, MD, Kerry J. Savage, MD MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Eric L. Sievers, MD, Anas Younes, MD

Blood (2012) 120 (21): 3689.

https://doi.org/10.1182/blood.V120.21.3689.3689

Published: 2012

Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Blood (2012) 120 (21): 3701.

https://doi.org/10.1182/blood.V120.21.3701.3701

Published: 2012

Journal Articles

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).

Luis F. Porrata, MD, Kay M. Ristow, Thomas M Habermann, MD, Thomas E. Witzig, MD, Joseph P. Colgan, MD, David J. Inwards, MD, Stephen M Ansell, M.D., Ph.D., Ivana N. Micallef, MD, Patrick B. Johnston, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2012) 120 (21): 2634.

https://doi.org/10.1182/blood.V120.21.2634.2634

Published: 2012

Journal Articles

Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.

Lucy S. Hodge, PharmD, Ph.D., Steven C. Ziesmer, Frank J Secreto, Ph.D., Zhi-Zhang Yang, MD, Anne J. Novak, Ph.D., Stephen M. Ansell, M.D., Ph.D.

Blood (2012) 120 (21): 2688.

https://doi.org/10.1182/blood.V120.21.2688.2688

Published: 2012

Journal Articles

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Craig Reeder, MD, Stephen M Ansell, M.D., Ph.D., Katherine Gano, Amylou C. Dueck, PhD, Christopher Conley, MD, Grzegorz S. Nowakowski, Kelly Curtis, MD, John Camoriano, MD, Jose Leis, MD, PhD, James L Slack, MD, Riccardo Valdez, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Keith Stewart, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2741.

https://doi.org/10.1182/blood.V120.21.2741.2741

Published: 2012

Journal Articles

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

Stephen M. Ansell, M.D., Ph.D., Joseph M. Connors, MD, Steven I. Park, MD, Megan M. O'Meara, MD, Anas Younes, MD

Blood (2012) 120 (21): 798.

https://doi.org/10.1182/blood.V120.21.798.798

Published: 2012

Journal Articles

Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

James M. Foran, MD, FRCPC, Cristine Allmer, BS, Alice H Wang, BA, Carrie A. Thompson, MD, Jennifer L. Kelly, PhD, MPH, Grzegorz S. Nowakowski, MD, Matthew J Maurer, MS, Susan L Slager, PhD, David J. Inwards, MD, Stephen M. Ansell, M.D., Ph.D., Thomas E. Witzig, MD, Brian K Link, MD, Thomas M Habermann, MD, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 684.

https://doi.org/10.1182/blood.V120.21.684.684

Published: 2012

Journal Articles

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Grzegorz S. Nowakowski, MD, Betsy R. LaPlant, Craig Reeder, MD, James M. Foran, MD, FRCPC, Luis F. Porrata, MD, William R Macon, MD, Patrick B. Johnston, MD, PhD, Candido E. Rivera, MD, Thomas M Habermann, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Garth D Nelson, Stephen M. Ansell, M.D., Ph.D., Thomas E. Witzig, MD

Blood (2012) 120 (21): 689.

https://doi.org/10.1182/blood.V120.21.689.689

Published: 2012

Journal Articles

Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)

Kirupananthan Seenithamby, Angela Dispenzieri, MD, Martha Q Lacy, MD, Shaji K. Kumar, MD, Francis K Buadi, M.D., Suzanne R Hayman, MD, David Dingli, M.D., Ph.D., Mark R Litzow, MD, Dennis A. Gastineau, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Stephen M. Ansell, M.D., Ph.D., Patrick B. Johnston, MD, PhD, Luis F. Porrata, MD, Mrinal M. Patnaik, MBBS, MD, William J Hogan, MBBCh, Morie Abraham A Gertz, MD

Blood (2012) 120 (21): 600.

https://doi.org/10.1182/blood.V120.21.600.600

Published: 2012

Journal Articles

MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.

Stephen M Ansell, M.D., Ph.D., Frank J Secreto, Ph.D., Michelle Manske, Esteban Braggio, Ph.D., Lucy S. Hodge, PharmD, Ph.D., Tammy Price-Troska, Steven C. Ziesmer, Asher Alban Chanan-Khan, M.D., Morie A Gertz, M.D., Ahmet Dogan, MD, PhD, James R Cerhan, MD, PhD, Anne J Novak, Ph.D.

Blood (2012) 120 (21): 2699.

https://doi.org/10.1182/blood.V120.21.2699.2699

Published: 2012

NARROW

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

Development Of a Human IgM Secreting Model Of Rpci-WM1 Through Xenografting In SCID Mice For In Vivo Drug Evaluation

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma

Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas

Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era

IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia

Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)

Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL , HLA-DRA , GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).

Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)

MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only